Fabino Life Sciences Ltd.
Snapshot View

34.00 ▼0%

27 January 2023, 04:01:00 PM

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fabinolife.com
Market Cap 7.14 Cr.
Enterprise Value(EV) 6.60 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 0.22 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 151.82 Trailing Twelve Months Ending 2022-03
Industry PE 32.22 Trailing Twelve Months Ending 2022-03
Book Value / Share 19.54 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.74 Calculated using Price: 34.00
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 0.21 Cr. 2,100,000 Shares
FaceValue 10
Company Profile
The company is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness focused consumer products. The company's core business is marketing of pharmaceutical formulation & products in domestic market through own distribution network and sales force under own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
1 Week
1 Month
+6.25%
3 Month
+9.68%
6 Month
+34.65%
1 Year
-4.76%
2 Year
5 Year
10 Year
4 years 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 0.02 10.80 3.05 1.74
Return on Capital Employed (%) 9.44 12.36 2.92 2.48
Return on Assets (%) 0.00 1.14 1.04 1.37

Balance Sheet View Details >>

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 1 1 1 4
Non Curr. Liab. 0 1 0 0
Curr. Liab. 8 2 1 0
Minority Int.
Equity & Liab. 9 4 2 5
Non Curr. Assets 1 1 0 0
Curr. Assets 8 3 2 4
Misc. Exp. not W/O
Total Assets 9 4 2 5

Profit Loss View Details >>

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Net Sales 3 8 3 4
Other Income 0
Total Income 3 8 3 4
Total Expenditure -2 -7 -3 -4
PBIDT 0 0 0 0
Interest 0 0 0 0
Depreciation 0 0 0 0
Taxation 0 0 0
Exceptional Items
PAT 0 0 0
Adjusted EPS 5 0 0

Cash Flow View Details >>

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 2 0 -2
Cash Fr. Inv. 0 0 0
Cash Fr. Finan. 0 -2 0 2
Net Change 0 0 1
Cash & Cash Eqvt 0 0 0 1

Shareholding Pattern View Details >>

2 Qtrs 2022-03 (%) 2022-09 (%)
Promoter 56.82 56.82
Public 43.18 43.18
Depository Receipts 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00

Announcements View Details >>

Thu, 12 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 dated January 11 2023 received from M/s Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company.
Thu, 24 Nov 2022
Board Meeting Outcome for Revised Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2022
In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held on November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed.
Wed, 09 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For Half Year Ended September 30 2022
In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held today i.e. November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed.

Technical Scans View Details >>

Fri, 27 Jan 2023
Higher Trade Quantity Higher Trade Quantity
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Close Above Last Month High Close Above Last Month High
High Increase in 1 Month High Increase in 1 Month

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 246,567.66 1,027.65 +2.0%
Cipla Ltd. 82,812.97 1,026.00 +0.1%
Divi's Laboratories Ltd. 76,573.08 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. 72,577.66 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. 61,039.46 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. 52,289.82 1,545.00 +0.3%
Abbott India Ltd. 44,198.55 20,800.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 58.54 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 31.39 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 25.59 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.92 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.70 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.92 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 50.12 20,800.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.46 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 3.65 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 6.31 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.30 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.20 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 16.28 20,800.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 0.04 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 0.00 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,800.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 798.70 20,800.00 +1.5%

FAQ's On Fabino Life Sciences Ltd.

What is Fabino Life Sciences share price?

Can I buy Fabino Life Sciences shares now?

What is the Market Cap of Fabino Life Sciences?

What are the key metrics to analyse Fabino Life Sciences?

What is the 52 Week High and Low of Fabino Life Sciences?